A 24 week efficacy study of inhaled Umeclidinium (UMEC) in patients of chronic obstructive pulmonary disease (COPD) using a novel dry powder inhaler (NDPI)

Trial Identifier: 117410
Sponsor: GlaxoSmithKline
NCTID:: NCT02184611
Start Date: May 2016
Primary Completion Date: November 2017
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
China Beijing, China, 100034
China Changsha, China, 410013
China Chongqing, China
China Chongqing, China, 400038
China Guangzhou, China, 510120
China Nanchang, China, 330006
China Shanghai, China, 200433
China, Guangdong Guangzhou, Guangdong, China, 510630
China, Guangdong Zhanjiang, Guangdong, China, 524001
China, Hainan Haikou, Hainan, China, 570311
China, Inner Mongolia Huhhot, Inner Mongolia, China, 010017
China, Jiangsu Wuxi, Jiangsu, China, 214023
China, Jiangxi Nanchang, Jiangxi, China, 330006
China, Jilin Changchun, Jilin, China, 130041
China, Liaoning Shenyang, Liaoning, China, 110004
China, Liaoning Shenyang, Liaoning, China, 110015
China, Ningxia Yinchuan, Ningxia, China, 750004
China, Shandong Jinan, Shandong, China, 250013
China, Shandong Qingdao, Shandong, China, 266071
China, Shanxi Taiyuan, Shanxi, China
China, Zhejiang Hangzhou, Zhejiang, China
South Korea Gyeonggi-do, South Korea, 410-719
South Korea Seoul, South Korea, 130-709
South Korea Seoul, South Korea, 130-872
South Korea Seoul, South Korea, 380-704
South Korea Suwon, South Korea, 442-723